Acrivon Therapeutics, Inc. (NASDAQ: ACRV), a clinical stage biopharmaceutical company with a market capitalization of $184 million and an impressive 60% stock return over the past year, announced that ...

Acrivon Therapeutics said the Food and Drug Administration has granted Breakthrough Device designation for its ACR-368 OncoSignature assay, an immunofluorescence assay for the identification of ...

The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ...

A new nasal delivery method for amifostine could protect healthy tissue during pancreatic cancer radiation therapy, potentially improving survival and expanding treatment options. A novel approach ...

Researchers at University of the Pacific in Stockton have developed a long-acting opioid overdose-reversal drug-delivery system that could save lives.

Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in preclinical models tested in mice. The novel drug CT-179 was ...

Brain cancer is the second-leading cause of death in children in the developed world. For the children who survive, standard ...

New gene therapies could transform sickle cell treatment forever. A future without pain crises or hospitalizations may finally be within reach.

Rheumatoid arthritis (RA) is an autoimmune disorder affecting millions worldwide, causing chronic inflammation, debilitating ...

Tonix Pharmaceuticals (TNXP) stock plunged after the company carried out a 1-for-100 reverse stock split as it awaits approval for its ...

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.